Weeks 5-10 execution — layering Thymosin Alpha-1 and LL-37

Phase 2 stack on top of the maintenance Phase 1 floor

By Week 5 the gut barrier work from Phase 1 has done its job. BPC-157 has been repairing tight junctions and mucosal lining for four weeks. KPV has been throttling NF-kB translocation and pulling IL-10 up. The substrate is healing. But a healed wall around a misfiring immune system and a biofilm-protected microbial overgrowth is a wall that will breach again. Phase 2 is where you address what was actually driving the leak.

The three-layer immune model the practitioner corpus uses to think about chronic gut inflammation is: Layer 1 — fuel cutoff (KPV throttles NF-kB, upregulates IL-10), Layer 2 — pathogen burden disruption (LL-37 dismantles biofilms shielding chronic infection), Layer 3 — retraining (Thymosin Alpha-1 educates T-cells and recalibrates immune intelligence). Phase 1 ran Layer 1. Phase 2 layers in Layers 2 and 3 on top of it.

What's actually happening at the cellular level

LL-37 is the body's own antimicrobial peptide. It does something antibiotics cannot — it attacks biofilms at a structural level. Biofilms are organized bacterial communities encased in a polysaccharide matrix that physically shields the bacteria from antibiotic penetration. They're the reason chronic gut infections, SIBO, and persistent inflammatory states keep recurring after every round of rifaximin or metronidazole. The bugs are still there. The biofilm just regrew. LL-37 punches holes in the matrix. The substrate identifies this gap as the "missing piece" in chronic infection cases that fail repeated antibiotic courses.

Thymosin Alpha-1 is immune intelligence, not immune amplification. This distinction matters. TA-1 doesn't push the immune system harder — it teaches T-cells what to attack and what to leave alone. In leaky-gut-driven autoimmune drift, the immune system has lost the ability to discriminate self from non-self because four-plus years of antigenic leakage through compromised tight junctions trained it to be paranoid. TA-1 elevates lymphocyte counts, restores Th1/Th2 balance, and rebuilds the regulatory T-cell population that should have been suppressing the inappropriate reactivity in the first place. The substrate places TA-1 in the top four "most critical stack" compounds a leading practitioner would carry if limited.

These two compounds work on opposite ends of the same problem. LL-37 reduces the antigenic load coming from biofilm-protected gut flora. TA-1 retrains the immune system that was overreacting to that load. Run together, they collapse the chronic inflammation cycle from both sides — fewer triggers, smarter responder.

The reason this is a Phase 2 protocol, not a Phase 1 protocol, is sequencing. Hit a compromised gut barrier with LL-37 too early and you disrupt beneficial flora before BPC-157 and KPV have rebuilt the substrate they live on. Hit a hair-trigger immune system with TA-1 too early and you risk amplifying inappropriate responses against a barrier that's still leaking antigens. Phase 1 has to land first.

Protocol prescription

LL-37 alternative dosing (acute/aggressive protocols): the practitioner corpus also cites 200 mcg (20 IU on an insulin syringe) twice daily SubQ for short courses targeting confirmed parasitic or persistent SIBO presentations. Use the 50–100 mcg daily range as the default for general leaky-gut Phase 2; reserve the higher 2x/day dose for confirmed pathogen burden with practitioner-grade lab evidence.

Injection logistics for the Phase 2 layered stack:

• TA-1 and LL-37 are separate compounds — do not mix in the same syringe. The substrate is explicit: do not combine peptides in one barrel unless the protocol specifically directs it (TB-500 + GHK-Cu is one of the few accepted combinations; TA-1 + LL-37 is not).
• Use a 29-gauge insulin syringe for both. Rotate injection sites clockwise around the navel, at least 2 inches out. Lipodystrophy from repeated site reuse will compromise absorption by Week 8 if you don't rotate.
• TA-1 on Monday and Thursday. LL-37 daily. BPC-157 continues twice daily. That's an honest injection burden — plan for it before Week 5.

What you should feel — week-by-week

• Week 5 — Nothing dramatic. LL-37 may produce mild flushing or warmth at the injection site within the first 30 minutes. This is expected and resolves. Loading TA-1; the immune effects compound over weeks, not days.
• Week 6 — Some users report a transient "die-off" type response — fatigue, mild GI looseness, headache — as biofilm disruption releases bacterial debris into circulation. If this hits, hold LL-37 dose at the lower end (50 mcg) and continue. The window is typically 3–7 days. The corpus describes this as a sign LL-37 is working, not a side effect to avoid.
• Week 7–8 — Bloating reduction becomes more consistent. Food reactivity that survived Phase 1 begins to ease. Skin clarity often improves in parallel — the gut-skin axis is responding.
• Week 9–10 — Lymphocyte count, if you pulled labs at Week 6, should be trending up. Energy stabilizes. The "inflammation hum" that defines chronic leaky gut — the low-grade malaise that's been background noise for years — frequently quiets.

What's NOT happening yet

• LL-37 is not sterilizing your gut. It disrupts biofilms. It does not eradicate the underlying microbial population, and it should not. A 4–6 week cycle is a deliberate cap — running longer risks collateral damage to beneficial flora that you spent Phase 1 protecting.
• TA-1 is not an immunosuppressant. If you have an active autoimmune flare, TA-1 will not "calm it down" in the way prednisone would. It modulates over weeks. Expect lab changes (TPO, ANA, CRP) on a 12–16 week horizon, not a 2-week horizon.
• You are not done with Phase 1. BPC-157 and KPV continue through Phase 2. Stopping the barrier-repair floor while you run the immune-retraining layer is a common mistake that produces partial response by Week 10. The protocol is additive, not sequential-replace.
• Symptom relief is not the endpoint. Lab trajectory is. CRP, lymphocyte subset panel, anti-TPO if relevant, comprehensive stool analysis at Week 12 — these are the markers that confirm the protocol did what symptom diaries can only suggest.

The practitioner corpus describes this layering. Track it. Adjust.